Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas

• Status: Completed
• Trial end date: 2013-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate both enzastaurin and bevacizumab in the treatment of recurrent malignant gliomas.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Collaborator: Genentech, Inc.
• Treatments: Anticonvulsants; Bevacizumab

Criteria

Inclusion Criteria:

• Participant must be at least 18 years old

• Participant must have been diagnosed with a recurrent brain tumor by magnetic resonance imaging (MRI) scan

• Participant must be willing to practice adequate contraception

• Participant must be able to swallow the enzastaurin tablets whole and receive bevacizumab intravenously

• Participant must agree to use the study drug only as instructed by your study doctor and staff.

Exclusion Criteria:

• Women who are pregnant or breastfeeding

• Participants who have significant heart, liver, kidney, or psychiatric disease

• Participants who have an active infection

• Participants who have any recent bleeding in the brain

• Participants who are taking any anti-coagulation or anti-platelet medication [including aspirin, non-steroidal anti-inflammatories, Cyclooxygenase-2 (COX-2) inhibitors]